

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

ANNOUNCEMENT OF 2010 ESTIMATED ANNUAL RESULTS

This announcement is made pursuant to Rule 13.09 of the Listing Rules.

Based on the preliminary management accounts prepared by the Group in accordance with HKFRSs, the net profit of the Group for the year ended 31 December 2010 is expected to be at least 1.76 times of that for the year ended 31 December 2009.

The financial information of the Group for the year ended 31 December 2010 referred to in this announcement is preliminary, unaudited, and may be different from the annual financial information to be published. The Board confirms that the disclosure of the financial information of the Group for the year ended 31 December 2010 referred to in this announcement is made after due and careful enquiry.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

This announcement is made pursuant to Rule 13.09 of the Listing Rules.

The board of the directors (the “Board”) of The United Laboratories International Holdings Limited (the “Company”) announces the estimated annual results of the Company and its subsidiaries (the “Group”) for the year ended 31 December 2010 as follows:

(1) Estimated results for the year ended 31 December 2010

Based on the preliminary management accounts prepared by the Group for the year ended 31 December 2010 in accordance with Hong Kong Financial Reporting Standards (“HKFRSs”), the estimated net profit of the Group for the year ended 31 December 2010 is expected to be at least 1.76 times of that for the year ended 31 December 2009. Detailed financial information will be published in the forthcoming 2010 annual report of the Company.

The financial information of the Group for the year ended 31 December 2010 referred to in this announcement is preliminary, unaudited, and may be different from the annual financial information to be published. The Board confirms that the disclosure of the financial information of the Group for the year ended 31 December 2010 referred to in this announcement is made after due and careful enquiry.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

(2) Annual results for 2009

The net profit attributable to the shareholders of the Company for the year ended 31 December 2009 is HK\$541,443,000.

The basic earnings per share of the Company for the year ended 31 December 2009 is HK\$0.451.

The above financial figures were prepared in accordance with HKFRSs.

(3) Reason for increase in results

The increase in net profit for the year ended 31 December 2010 is mainly attributable to the satisfactory increase in sales of intermediate products, bulk medicine products and finished products of the Group, and effective cost control.

By Order of the Board
**The United Laboratories
International Holdings Limited**
Choy Kam Lok
Chairman

Hong Kong, 4 March 2011

As at the date of this announcement, the Board comprises Mr. Choy Kam Lok, Ms. Peng Wei, Mr. Leung Wing Hon, Mr. Tsoi Hoi Shan, Ms. Zou Xian Hong, Ms. Zhu Su Yan and Mr. Fang Yuping as executive directors; Ms. Choy Siu Chit as non-executive director; and Mr. Chong Peng Oon, Mr. Huang Bao Guang and Mr. Song Ming as independent non-executive directors.